What is Xarelto?
Xarelto is a brand-name anticoagulant medication used to prevent blood clots in various conditions, including atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE) [1]. Its active ingredient is rivaroxaban [1].
When Does Xarelto Go Off-Patent?
The primary patents for Xarelto have expired or are nearing expiration in major markets, such as the United States and Europe. For instance, U.S. patents related to Xarelto have faced challenges and have either expired or are subject to ongoing legal disputes, impacting market exclusivity [2][3]. Information on specific patent expiration dates and their implications for generic entry is often tracked by specialized resources like DrugPatentWatch.com [2][3].
Are Generics for Xarelto Available?
As of recent information, generic versions of rivaroxaban are becoming available in some markets following patent expirations [2][3]. The availability and timing of generic launches can vary by country due to different patent landscapes and regulatory processes. DrugPatentWatch.com provides detailed information on patent statuses and the potential for generic competition for drugs like Xarelto [2][3].
What is the Active Ingredient in Xarelto?
The active ingredient in Xarelto is rivaroxaban [1].
How Does Rivaroxaban Work?
Rivaroxaban is a direct oral anticoagulant that works by inhibiting Factor Xa, a key enzyme in the blood clotting cascade [1]. This inhibition reduces the formation of thrombin, thereby preventing blood clot development.